For many people living with kidney disease, the possibility of sudden kidney injury can feel worrying and unpredictable. Serious infections, major surgery, or time spent in intensive care can place additional strain on the kidneys, sometimes leading to acute kidney injury (AKI). For patients and families, this can add to an already heavy emotional and physical burden.
Recently, researchers from Bristol reported findings from laboratory studies that may help scientists better understand how kidney damage occurs during acute kidney injury, and how it might one day be reduced.
What is this acute kidney injury research about?
The study looked at how kidney cells are damaged during acute kidney injury. Researchers focused on the role of mitochondria, the parts of cells responsible for producing energy. When mitochondria stop working properly, kidney cells can no longer function as they should.
The researchers found that certain fatty molecules, known as ceramides, can damage mitochondria during severe illness. In experimental models, reducing these ceramides helped protect kidney cells and prevented acute kidney injury from developing.
You can read the full original article from the University of Bristol here: New breakthrough shows promise for protecting people against kidney damage in intensive care.
Why this matters for kidney patients
Acute kidney injury is common in hospital settings and can affect people with and without pre-existing kidney disease. For those already living with chronic kidney disease, AKI can lead to a permanent loss of kidney function or increase the likelihood of needing dialysis.
At present, treatment for AKI is largely supportive. There are no medicines that specifically prevent this type of injury. Research that helps explain why kidney cells fail is an important step towards better care in the future. Understanding the role of ceramides could eventually lead to treatments that protect kidneys during serious illness.
For people in Greater Manchester and the North West, advances in understanding acute kidney injury support the expertise at Manchester Royal Infirmary, where critical care and kidney medicine teams work together.
What should patients understand now?
It is important to be clear that this research is still at an early, experimental stage. The findings come from laboratory and animal studies, not from trials in people. This means it is not a treatment and not something currently available to patients.
However, the work helps researchers better understand the biological processes behind kidney injury. Over time, this knowledge may support the development of safer, more effective ways to protect kidneys during serious illness. If you have questions about your own kidney care, your renal team remains the best source of advice.
At MRIKPA, we follow research developments like this to help patients and carers stay informed about how kidney care may evolve in the years ahead. We will continue to monitor progress and share updates as they become clearer.
If you would like to talk to someone about how this research might relate to your own situation, or if you simply want to connect with others who understand, our volunteers are always happy to hear from you. Get in touch at support@mrikpa.org.uk or call us on 07745 242 684.
This article is provided for general information and awareness purposes only and was believed to be accurate at the time of publishing. It is not intended as medical advice — please always consult your doctor or renal team for guidance on your individual circumstances. Images used are for illustration purposes only and may not be medically or editorially accurate. While we take every care, errors can occur. If you spot an inaccuracy, please let us know at support@mrikpa.org.uk.
